[go: up one dir, main page]

SG11202006311SA - Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators - Google Patents

Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators

Info

Publication number
SG11202006311SA
SG11202006311SA SG11202006311SA SG11202006311SA SG11202006311SA SG 11202006311S A SG11202006311S A SG 11202006311SA SG 11202006311S A SG11202006311S A SG 11202006311SA SG 11202006311S A SG11202006311S A SG 11202006311SA SG 11202006311S A SG11202006311S A SG 11202006311SA
Authority
SG
Singapore
Prior art keywords
intermediates
preparation
guanylate cyclase
soluble guanylate
novel processes
Prior art date
Application number
SG11202006311SA
Inventor
Debra Jane Wallace
Fenger Zhou
Yuguang Wang
Takashi Nakai
Vishnu Vardhan Reddy Karnati
Wayne C Schairer
William Kissel
Song Xue
Ahmad Hashash
Original Assignee
Cyclerion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2018/076982 external-priority patent/WO2019161534A1/en
Application filed by Cyclerion Therapeutics Inc filed Critical Cyclerion Therapeutics Inc
Publication of SG11202006311SA publication Critical patent/SG11202006311SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202006311SA 2018-01-10 2019-01-10 Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators SG11202006311SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862615678P 2018-01-10 2018-01-10
PCT/CN2018/076982 WO2019161534A1 (en) 2018-02-22 2018-02-22 Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators
PCT/US2019/013060 WO2019140095A1 (en) 2018-01-10 2019-01-10 Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators

Publications (1)

Publication Number Publication Date
SG11202006311SA true SG11202006311SA (en) 2020-07-29

Family

ID=65279655

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202006311SA SG11202006311SA (en) 2018-01-10 2019-01-10 Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators

Country Status (17)

Country Link
US (4) US11274096B2 (en)
EP (3) EP4249469A3 (en)
JP (2) JP7357621B2 (en)
KR (3) KR102739727B1 (en)
CN (3) CN118184645A (en)
AU (3) AU2019206560B2 (en)
BR (1) BR112020013985A2 (en)
CA (1) CA3087943A1 (en)
CL (3) CL2020001814A1 (en)
ES (1) ES2963447T3 (en)
IL (3) IL319883A (en)
JO (1) JOP20200165A1 (en)
MA (2) MA71753A (en)
MX (3) MX2020007364A (en)
SG (1) SG11202006311SA (en)
TW (1) TWI821237B (en)
WO (1) WO2019140095A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109563077A (en) 2016-07-07 2019-04-02 铁木医药有限公司 It is used to prepare the new method of soluble guanylate cyclase stimulant
KR102739727B1 (en) 2018-01-10 2024-12-05 사이클리온 테라퓨틱스, 인크. Novel methods and intermediates for the preparation of available guanylate cyclase stimulators
AU2023412238A1 (en) * 2022-12-21 2025-07-03 Sunshine Lake Pharma Co., Ltd. Crystal form of fluorine-substituted indazole compound and use thereof
WO2024131850A1 (en) * 2022-12-21 2024-06-27 广东东阳光药业股份有限公司 Crystal form of fluorine-substituted indazole compound and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2588465T3 (en) * 2010-06-30 2017-05-01 Ironwood Pharmaceuticals Inc SGC stimulators
RS63108B1 (en) * 2013-03-15 2022-04-29 Cyclerion Therapeutics Inc Sgc stimulators
WO2015106268A1 (en) * 2014-01-13 2015-07-16 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
BR112017005248A2 (en) * 2014-09-17 2017-12-12 Ironwood Pharmaceuticals Inc sgc stimulators
WO2016044447A1 (en) * 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
CN108883071A (en) * 2015-11-30 2018-11-23 铁木医药有限公司 Solid dispersions comprising sGC stimulant
CA3029376A1 (en) 2016-07-07 2018-01-11 Ironwood Pharmaceuticals, Inc. Novel processes for preparation of soluble guanylate cyclase stimulators
CN109563077A (en) 2016-07-07 2019-04-02 铁木医药有限公司 It is used to prepare the new method of soluble guanylate cyclase stimulant
KR102739727B1 (en) 2018-01-10 2024-12-05 사이클리온 테라퓨틱스, 인크. Novel methods and intermediates for the preparation of available guanylate cyclase stimulators

Also Published As

Publication number Publication date
MA51565A (en) 2020-11-18
EP4570797A2 (en) 2025-06-18
CL2020001814A1 (en) 2020-11-06
AU2019206560A1 (en) 2020-07-30
EP4249469A3 (en) 2023-12-27
AU2019206560B2 (en) 2023-08-24
US20230339928A1 (en) 2023-10-26
KR20200106920A (en) 2020-09-15
US11708361B2 (en) 2023-07-25
WO2019140095A8 (en) 2020-06-18
CN118184645A (en) 2024-06-14
CN111902410A (en) 2020-11-06
US20220024909A1 (en) 2022-01-27
KR20250002720A (en) 2025-01-07
CN118221665A (en) 2024-06-21
AU2025202281A9 (en) 2025-05-15
IL314714A (en) 2024-10-01
JP2021511299A (en) 2021-05-06
EP4249469A2 (en) 2023-09-27
CA3087943A1 (en) 2019-07-18
EP3737679A1 (en) 2020-11-18
JOP20200165A1 (en) 2022-10-30
US20240391911A1 (en) 2024-11-28
AU2023270260A1 (en) 2023-12-07
US12030874B2 (en) 2024-07-09
MA71753A (en) 2025-05-30
CN111902410B (en) 2024-04-19
AU2025202281A1 (en) 2025-04-17
TW202402741A (en) 2024-01-16
IL275748B2 (en) 2025-01-01
MX2023000044A (en) 2023-02-01
US11274096B2 (en) 2022-03-15
IL275748B1 (en) 2024-09-01
CL2022000907A1 (en) 2022-10-21
IL319883A (en) 2025-05-01
JP7357621B2 (en) 2023-10-06
EP3737679B1 (en) 2023-09-06
IL275748A (en) 2020-08-31
MX2020007364A (en) 2020-11-18
JP2023182647A (en) 2023-12-26
MX2023000045A (en) 2023-02-01
US12275724B2 (en) 2025-04-15
US20210053962A1 (en) 2021-02-25
KR20250048609A (en) 2025-04-09
TW201932450A (en) 2019-08-16
BR112020013985A2 (en) 2020-12-01
KR102739727B1 (en) 2024-12-05
ES2963447T3 (en) 2024-03-27
EP3737679C0 (en) 2023-09-06
CL2022000904A1 (en) 2022-10-21
WO2019140095A1 (en) 2019-07-18
TWI821237B (en) 2023-11-11

Similar Documents

Publication Publication Date Title
IL275748A (en) Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators
GB202106894D0 (en) Process for the preparation of 3alpha-hydroxy-5#LPHA-Pregnan-20-one (brexanolone)
ZA202101214B (en) Process and intermediates for the preparation of bilastine
HUE062956T2 (en) Processes for the preparation of niraparib and intermediates thereof
ZA202003590B (en) Process for the preparation of opicapone and intermediates thereof
IL260665B (en) Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and " azd9291 aniline" or a salt thereof
IL263995B (en) Novel processes for preparation of soluble guanylate cyclase stimulators
IL289904A (en) Process for the preparation of biphenylamines
IL263994B (en) State-of-the-art processes for the preparation of soluble guanylate cyclase stimulators
LT3765440T (en) Process for the preparation of n-alkyl-nitratoethylnitramines
IL281254A (en) Process for the preparation of lenvatinib
IL272837A (en) Process for the preparation of tubulysins and intermediates thereof
IL276852A (en) Process for preparing soluble guanylate cyclase stimulators
PL3737685T3 (en) Process for the preparation of crisaborole and its intermediates
PL3599256T3 (en) Process for the preparation of polyorganosiloaxnes
HK40103207A (en) Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators
IL278549B2 (en) Intermediates and processes for the preparation of linagliptin and its salts
IL281090A (en) Alternative processes for the preparation of tubulysins and intermediates thereof
HUE067201T2 (en) Process and intermediate for the preparation of oxetan-2-ylmethanamine
ZA202107053B (en) Novel process for the preparation of filgotinib and intermediates thereof
HK40103206A (en) Novel processes for preparation of soluble guanylate cyclase stimulators
HUP1800278A2 (en) Process for the preparation of boc-linagliptin
PT3969459T (en) Process and intermediates for the preparation of eldecalcitol
HK40034275A (en) Process for preparing soluble guanylate cyclase stimulators
HUP1800397A2 (en) Process for the preparation of lumateperone and salts thereof